JBIO vs NBIX · $868.2M cap vs P/E 45, rev $1.77B
Jade Biosciences, Inc. (JBIO) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Jade Biosciences, Inc. (JBIO) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
JBIO does not have a complete income-statement cache yet.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
JBIO currently screens at market cap $868.2M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the JBIO and NBIX stock pages for the full models.
Not investment advice.